Capital Performance Advisors LLP Stoke Therapeutics, Inc. Transaction History
Capital Performance Advisors LLP
- $325 Million
- Q3 2024
A detailed history of Capital Performance Advisors LLP transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 32 shares of STOK stock, worth $411. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32Holding current value
$411% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding STOK
# of Institutions
121Shares Held
53.5MCall Options Held
14KPut Options Held
8.8K-
Skorpios Trust8.91MShares$115 Million99.85% of portfolio
-
Black Rock Inc. New York, NY5.41MShares$69.6 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.72MShares$60.7 Million4.16% of portfolio
-
Baker Bros. Advisors LP New York, NY4.37MShares$56.2 Million0.78% of portfolio
-
Rtw Investments, LP New York, NY4.22MShares$54.3 Million0.95% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $507M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...